380 related articles for article (PubMed ID: 22050339)
21. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
22. Alternative molecular formats and therapeutic applications for bispecific antibodies.
Spiess C; Zhai Q; Carter PJ
Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
[TBL] [Abstract][Full Text] [Related]
23. Targeting T cells to tumor cells using bispecific antibodies.
Frankel SR; Baeuerle PA
Curr Opin Chem Biol; 2013 Jun; 17(3):385-92. PubMed ID: 23623807
[TBL] [Abstract][Full Text] [Related]
24. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
25. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
[TBL] [Abstract][Full Text] [Related]
26. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
Cyr MG; Mhibik M; Qi J; Peng H; Chang J; Gaglione EM; Eik D; Herrick J; Venables T; Novick SJ; Courouble VV; Griffin PR; Wiestner A; Rader C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442911
[TBL] [Abstract][Full Text] [Related]
28. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
29. Chemically Programmed Bispecific Antibodies in Diabody Format.
Walseng E; Nelson CG; Qi J; Nanna AR; Roush WR; Goswami RK; Sinha SC; Burke TR; Rader C
J Biol Chem; 2016 Sep; 291(37):19661-73. PubMed ID: 27445334
[TBL] [Abstract][Full Text] [Related]
30. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
Thakur A; Lum LG
Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
[TBL] [Abstract][Full Text] [Related]
31. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
[TBL] [Abstract][Full Text] [Related]
32. The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy.
Molema G; Kroesen BJ; Helfrich W; Meijer DK; de Leij LF
J Control Release; 2000 Feb; 64(1-3):229-39. PubMed ID: 10640660
[TBL] [Abstract][Full Text] [Related]
33. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
34. Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA; Kufer P; Lutterbüse R
Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
[TBL] [Abstract][Full Text] [Related]
35. Bispecific antibodies.
Brinkmann U; Kontermann RE
Science; 2021 May; 372(6545):916-917. PubMed ID: 34045345
[No Abstract] [Full Text] [Related]
36. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
Yuraszeck T; Kasichayanula S; Benjamin JE
Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
[TBL] [Abstract][Full Text] [Related]
37. Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.
Grandjenette C; Dicato M; Diederich M
Curr Pharm Biotechnol; 2015; 16(8):670-83. PubMed ID: 25941884
[TBL] [Abstract][Full Text] [Related]
38. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
39. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
40. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
